Chevy Chase Trust Holdings Inc. raised its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 81.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,239 shares of the company’s stock after buying an additional 5,497 shares during the quarter. Chevy Chase Trust Holdings Inc.’s holdings in Teva Pharmaceutical Industries were worth $215,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also bought and sold shares of the stock. Schwab Charles Investment Management Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 7.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock valued at $8,025,000 after acquiring an additional 17,116 shares during the last quarter. Boston Partners lifted its stake in shares of Teva Pharmaceutical Industries by 32.6% in the 2nd quarter. Boston Partners now owns 141,852 shares of the company’s stock valued at $4,712,000 after acquiring an additional 34,846 shares during the last quarter. First Trust Advisors LP lifted its stake in shares of Teva Pharmaceutical Industries by 10.5% in the 2nd quarter. First Trust Advisors LP now owns 612,724 shares of the company’s stock valued at $20,355,000 after acquiring an additional 58,414 shares during the last quarter. Advisors Asset Management Inc. lifted its stake in shares of Teva Pharmaceutical Industries by 37.6% in the 2nd quarter. Advisors Asset Management Inc. now owns 33,430 shares of the company’s stock valued at $1,111,000 after acquiring an additional 9,136 shares during the last quarter. Finally, KBC Group NV lifted its stake in shares of Teva Pharmaceutical Industries by 659.6% in the 2nd quarter. KBC Group NV now owns 385,011 shares of the company’s stock valued at $12,790,000 after acquiring an additional 334,327 shares during the last quarter. Institutional investors and hedge funds own 52.05% of the company’s stock.

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) traded up $0.05 on Monday, reaching $18.67. The company’s stock had a trading volume of 8,703,792 shares, compared to its average volume of 16,500,490. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Ltd has a 1-year low of $10.85 and a 1-year high of $38.31. The stock has a market cap of $18,907.76, a P/E ratio of 4.30 and a beta of 0.55.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th were paid a dividend of $0.085 per share. The ex-dividend date was Monday, November 27th. This represents a $0.34 annualized dividend and a yield of 1.82%. Teva Pharmaceutical Industries’s dividend payout ratio is -12.10%.

A number of equities research analysts have recently weighed in on the company. BidaskClub raised Teva Pharmaceutical Industries from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 13th. UBS set a $20.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Monday. Piper Jaffray Companies set a $16.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Thursday. Cantor Fitzgerald set a $17.00 target price on Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Monday, September 11th. Finally, BTIG Research boosted their target price on Teva Pharmaceutical Industries to $20.00 in a research note on Friday. Five analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Teva Pharmaceutical Industries has a consensus rating of “Hold” and an average price target of $20.68.

TRADEMARK VIOLATION WARNING: This story was reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/teva-pharmaceutical-industries-ltd-teva-position-boosted-by-chevy-chase-trust-holdings-inc/1771381.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.